International benchmarking of US immunology research [[electronic resource] /] / Panel on International Benchmarking of US Immunology Research, Committee on Science, Engineering, and Public Policy, National Academy of Sciences, National Academy of Engineering, Institute of Medicine

• Record Nr.: UNINA9910451478803321
• Pubbl/distr/stampa: Washington, DC, : National Academy Press, 1999
• Descrizione fisica: 1 online resource (60 p.)
• Disciplina: 616.079072
• Soggetti: Immunology - Research; Immunity; Electronic books.
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: "Prepublication copy."
• Nota di bibliografia: Includes bibliographical references.
• Nota di contenuto: ""INTERNATIONAL BENCHMARKING OF US IMMUNOLOGY RESEARCH""; ""Copyright""; ""PREFACE""; ""CONTENTS""; ""EXECUTIVE SUMMARY""; ""1 INTRODUCTION""; ""1.1 HOW IMPORTANT IS IT FOR THE UNITED STATES TO LEAD IN IMMUNOLOGY RESEARCH?""; ""1.2 WHAT IS IMMUNOLOGY?""; ""1.3 IMMUNOLOGY AS AN ACADEMIC DISCIPLINE""; ""1.4 WHAT IS THE INTERNATIONAL NATURE OF IMMUNOLOGY?""; ""1.5 WHAT ARE SOME CAVEATS?""; ""1.6 PANEL CHARGE AND RATIONALE""; ""2 BENCHMARKING RESULTS""; ""2.1 METHODS""; ""2.1.1 Reputation Survey""; ""2.1.2 Citation Analysis""; ""2.1.3 Journal Publication Analysis""; ""2.2 RESULTS""; ""2.2.1 Reputation Survey""""2.2.2 Citation Analysis""; ""2.2.3 Journal Publication Analysis""; ""2.3 SUMMARY""; ""3 KEY FACTORS""; ""3.1 FUNDING""; ""3.2 HUMAN RESOURCES""; ""3.3 INFRASTRUCTURE""; ""3.4 BIOTECHNOLOGY AND PHARMACEUTICAL FIRMS""; ""3.5 THE CLINICAL TRIAL""; ""4 LIKELY FUTURE POSITION""; ""4.1 FUNDING AND RESOURCE LIMITATIONS""; ""4.2 INCREASED COMPETITION FROM EUROPE AND OTHER COUNTRIES""; ""4.3 CLINICAL IMMUNOLOGY AND THE SHIFT TOWARD HMOS""; ""4.4 TRAINING OF US STUDENTS""; ""5 SUMMARY AND CONCLUSIONS""; ""5.1 THE UNITED STATES IS THE WORLD LEADER IN ALL THE MAJOR SUBFIELDS OF IMMUNOLOGY BUT IS ONLY AMONG THE WORLD LEADERS INâ€?""""5.2 FLEXIBILITY TO PURSUE ORIGINAL AND INNOVATIVE RESEARCH IDEAS HAS ATTRACTED BOTH DOMESTIC AND INTERNATIONAL HUMANâ€?""; ""5.3 INDUSTRIAL INTERESTS HAVE FOSTERED MANY STRIKING BREAKTHROUGHS IN IMMUNOLOGY""; ""5.4 A SCARCITY OF LARGE-SCALE CLINICAL TRIALS IN IMMUNOLOGY CAN BE ATTRIBUTED TO SHORTAGES OF FUNDING AND OF QUALIFIEDâ€?""; ""5.5 SHIFTING FEDERAL AND INDUSTRY PRIORITIES, A POTENTIAL REDUCTION IN ACCESS TO DOMESTIC AND FOREIGN TALENT, AND THEâ€?""; ""REFERENCES""""APPENDIX PANEL AND STAFF BIOGRAPHICAL INFORMATION""; ""STAFF""